%0 Journal Article
%A Chudasama, Priya
%A Renner, Marcus
%A Straub, Melanie
%A Mughal, Sadaf S
%A Hutter, Barbara
%A Kosaloglu-Yalcin, Zeynep
%A Schweßinger, Ron
%A Scheffler, Matthias
%A Alldinger, Ingo
%A Schimmack, Simon
%A Persigehl, Thorsten
%A Kobe, Carsten
%A Jäger, Dirk
%A von Kalle, Christof
%A Schirmacher, Peter
%A Beckhaus, Marie-Kristin
%A Wolf, Stephan
%A Heining, Christoph
%A Gröschel, Stefan
%A Wolf, Jürgen
%A Brors, Benedikt
%A Weichert, Wilko
%A Glimm, Hanno
%A Scholl, Claudia
%A Mechtersheimer, Gunhild
%A Specht, Katja
%A Fröhling, Stefan
%T Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
%J Clinical cancer research
%V 23
%N 4
%@ 1557-3265
%C Philadelphia, Pa. [u.a.]
%I AACR
%M DKFZ-2017-00432
%P 962 - 973
%D 2017
%X Purpose: Altered FGFR1 signaling has emerged as a therapeutic target in epithelial malignancies. In contrast, the role of FGFR1 in soft-tissue sarcoma (STS) has not been established. Prompted by the detection and subsequent therapeutic inhibition of amplified FGFR1 in a patient with metastatic leiomyosarcoma, we investigated the oncogenic properties of FGFR1 and its potential as a drug target in patients with STS.Experimental Design: The frequency of FGFR1 amplification and overexpression, as assessed by FISH, microarray-based comparative genomic hybridization and mRNA expression profiling, SNP array profiling, and RNA sequencing, was determined in three patient cohorts. The sensitivity of STS cell lines with or without FGFR1 alterations to genetic and pharmacologic FGFR1 inhibition and the signaling pathways engaged by FGFR1 were investigated using viability assays, colony formation assays, and biochemical analysis.Results: Increased FGFR1 copy number was detected in 74 of 190 (38.9
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27535980
%R 10.1158/1078-0432.CCR-16-0860
%U https://inrepo02.dkfz.de/record/119837